Sanoculis offers products related to vision protection and eyewear. The company provides options for different countries, suggesting a global reach and diverse product offerings.

Sanoculis

绵阳万江眼科医院 provides eye care services and was established in 2002. It has been recognized as a state-level tertiary eye hospital.

绵阳万江眼科医院

Sanoculis Ltd. | 1,441 followers on LinkedIn. Sanoculis offers MIMS®, Minimally Invasive Micro Sclerostomy, a novel, stent-less straightforward  Glaucoma surgery. | MIMS® creates a drainage channel to reduce IOP in Glaucoma patients, ensuring a long-lasting safe and controlled fluid flow, no stitches, eye-patch, implant or stent. It is designed to reduce the caring costs of Glaucomatous patients’ through simplicity, low cost, fewer post-surgical complications and less hospitalization.

Elad Shalev

RA Specialist at Sanoculis Ltd, Medical Devices

Tamara Kramarov Yaffe

Vice President of Quality Assurance and Regulatory Affairs at Sanoculis Ltd.

Maayan Noach-Shaharabani

Director, Global Surgical Training

Erna Kidron ארנה קידרון

Sanoculis Ltd.

Happy to share MIMS® latest article on Glaucoma Physician ! #mims #glaucoma #leavenothingbehind

Sanoculis wishes you a joyful Rosh Hashanah and a Happy New Jewish Year! As we celebrate this New Year amidst challenging times in Israel, may you find health, happiness, prosperity, and together, let’s work towards a brighter future for all.

#MINT ® MINT® is pending CE-mark approval MINT® is a registered trademark in Europe

Bausch + Lomb Announces New Scientific Data, Educational Events at ESCRS Read about Sanoculis's featured products (MIMS+MINT) https://bit.ly/3MrQALi * MINT is pending CE approval

#mims Bausch + Lomb Surgical #boothD35 #ESCRS

Bausch + Lomb Italia al Congresso Nazionale S.I.GLA. per i suoi 20 anni 🎉 Abbiamo parlato di soluzioni farmacologiche e chirurgiche di Bausch & Lomb per il trattamento del glaucoma e approfondito i vantaggi del MIMs – Minimally Invasive Micro Sclerostomy. Grazie a tutti coloro che sono passati a trovarci! 🙌🏻 👉🏻 Scopri di più sul MIMs qui ➡️ https://lnkd.in/dwz2Zt79 #seebetterlivebetter #bauschlombitalia #evento #SIGLA #chirurgia #chirurgiaoftalmica #glaucoma #innovazione #medicina

Metric
Company Name	Sanoculis	绵阳万江眼科医院
Symbol
MSH ID	COM:SANOCULIS	COM:WJYKYY
Market	PRIVATE	PRIVATE
Sector	Consumer Goods	Healthcare & Health Services
Industry	Optical Retail	Healthcare
Country	US	CN
Stage
Employee Count
Website	sanoculis.com	wjykyy.com
LinkedIn	sanoculis
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

SANO

COM:SANOCULIS

Sanoculis

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue